Splanchnic and renal vasoconstrictor and metabolic responses to neuropeptide Y in resting and exercising man.
The local clearance of neuropeptide Y (NPY) and whether NPY influences splanchnic and renal metabolism in man have not been investigated previously. The influence of NPY on splanchnic and renal blood flows at physiologically elevated levels has also not been investigated. The effects of a 40-min constant NPY infusion (3 pmol kg-1 min-1) at rest and during 130 min of exercise (50% of VO2max) were studied in six healthy subjects and compared with resting and exercising subjects receiving no NPY. Blood samples were drawn from arterial, hepatic and renal vein catheters for the determination of blood flows (indicators: cardiogreen and para-aminohippuric acid [PAH]), NPY, catecholamines, glucose, lactate and glycerol. NPY infusion was accompanied by: (1) significant fractional extraction of NPY-like immunoreactivity (NPY-Li) by splanchnic tissues at rest (58 +/- 5%) and during exercise (53 +/- 6%), while no arterial-venous differences could be detected across the kidney; (2) a reduction in splanchnic and renal blood flows of up to 18 and 13% respectively (P less than 0.01-0.001) at rest without any additional changes during exercise; and (3) metabolic changes as reflected in: (a) a more marked fall in arterial glucose during exercise compared to the reference group (P less than 0.05); (b) a 35% lower splanchnic glucose release (P less than 0.01) during exercise due to diminished glycogenolysis (P less than 0.01); and (c) a lower arterial lactate level (18% P less than 0.05) together with unchanged splanchnic lactate uptake during exercise, suggesting reduced lactate production by extrahepatic tissues. The disappearance of plasma NPY-Li after the infusions was biphasic with two similar half-lives at rest (4 and 39 min) and during exercise (3 and 43 min).
Ahlborg
G
G
Department of Clinical Physiology, Karolinska Hospital, Stockholm, Sweden.
Weitzberg
E
E
Sollevi
A
A
Lundberg
J M
JM
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D015444:Exercise / Q000502:physiology*; D005990:Glycerol / Q000097:blood; D006439:Hemodynamics; D006801:Humans; D007275:Injections, Intravenous; D007773:Lactates / Q000097:blood; D008297:Male; D009478:Neuropeptide Y / Q000493:pharmacokinetics / Q000494:pharmacology*; D009638:Norepinephrine / Q000097:blood; D010101:Oxygen Consumption; D012079:Renal Circulation / Q000187:drug effects*; D013152:Splanchnic Circulation / Q000187:drug effects*; D014661:Vasoconstriction / Q000187:drug effects
D001786:Blood Glucose; D007773:Lactates; D009478:Neuropeptide Y; D005990:Glycerol; D009638:Norepinephrine